Unlike traditional drug discovery efforts that have focused exclusively on the human side of the equation, Second Genome is working on therapeutic product breakthroughs by focusing on how the microbiota interacts with itself and with its human host to impact health and disease.
Second Genome is leveraging microbiome science to develop novel therapeutics in clinical indications with large unmet needs. With the intersect between the microbiome and human health growing increasingly important in disease area research, Second Genome has focused on two key disease areas that have been tightly linked to microbial activity.
Second Genome is engaged in a number of strategic collaborations for the discovery and development of microbiome-modulating therapeutics. These partnerships help identify and develop product candidates that modulate microbe-microbe and microbe-host interactions across multiple disease areas for its partners.
The research and development activities at Second Genome are focused on applying microbiome science to the discovery and development of novel life-saving therapeutics.